Clarisse Eveno1,2, Aminata Haidara2, Ibrahim Ali2, Cynthia Pimpie2, Massoud Mirshahi2, Marc Pocard3,4. 1. Department of Oncologic & Digestive Surgery, AP-HP, Hospital Lariboisière, Paris Cedex 10, France. 2. Université Paris Diderot, Sorbonne Paris Cité, CART, Carcinomatosis Angiogenesis Translational Research, INSERM U965, Paris, France. 3. Department of Oncologic & Digestive Surgery, AP-HP, Hospital Lariboisière, 2 rue Ambroise Paré, 75475 Paris Cedex 10, France. 4. Université Paris Diderot, Sorbonne Paris Cité, CART, Carcinomatosis Angiogenesis Translational Research, INSERM U965, 74575 Paris, France.
Abstract
BACKGROUND: Pressurised intraperitoneal aerosol chemotherapy (PIPAC) is a novel technique of intraperitoneal chemotherapy devoted to unresectable peritoneal metastasis (PM). The first results obtained with PIPAC in preclinical models of colon cancer are presented here. METHODS: In vitro, PIPAC (normotherm oxaliplatin at 0.028 mg/mL for 10 min at 1.6 bars) and HIPEC (hyperthermic oxaliplatin at 0.14 mg/mL for 30 min) were compared using the apoptosis and proliferation assay on two colon cancer cell lines (LS 174 and CT 26); ex vivo tumours from an orthotopic mouse model of PM and non-tumour peritoneum from a patient treated according to the two modalities were assessed, investigating the percentage of penetration of oxaliplatin in the tumour and oxaliplatin concentration below the peritoneum. In vivo, a mouse model of colon (CT 26) PM was used to create a PIPAC model (same modalities) for the comparison of IV oxaliplatin (at 5 mg/mL). RESULTS: In vitro, the rate of apoptotic and proliferative cells as well as the level of oxaliplatin penetration in tumour nodes was higher in PIPAC groups with less systemic passage through the peritoneum. In vivo, in the colon PM mouse model, the peritoneal cancer index (PCI) was decreased to the same level using PIPAC or IV oxaliplatin. Systemic passage was lower in the PIPAC group. CONCLUSIONS: PIPAC with low-dose oxaliplatin is efficient in both in vitro and in vivo models of colon PM. Lower concentrations of chemotherapy are needed in PIPAC to achieve the same effect as IV chemotherapy on PCI. With a very low systemic oxaliplatin passage, this technique of drug delivery seems to be as effective as IV delivery for PM control.
BACKGROUND: Pressurised intraperitoneal aerosol chemotherapy (PIPAC) is a novel technique of intraperitoneal chemotherapy devoted to unresectable peritoneal metastasis (PM). The first results obtained with PIPAC in preclinical models of colon cancer are presented here. METHODS: In vitro, PIPAC (normotherm oxaliplatin at 0.028 mg/mL for 10 min at 1.6 bars) and HIPEC (hyperthermic oxaliplatin at 0.14 mg/mL for 30 min) were compared using the apoptosis and proliferation assay on two colon cancer cell lines (LS 174 and CT 26); ex vivo tumours from an orthotopic mouse model of PM and non-tumour peritoneum from a patient treated according to the two modalities were assessed, investigating the percentage of penetration of oxaliplatin in the tumour and oxaliplatin concentration below the peritoneum. In vivo, a mouse model of colon (CT 26) PM was used to create a PIPAC model (same modalities) for the comparison of IV oxaliplatin (at 5 mg/mL). RESULTS: In vitro, the rate of apoptotic and proliferative cells as well as the level of oxaliplatin penetration in tumour nodes was higher in PIPAC groups with less systemic passage through the peritoneum. In vivo, in the colon PM mouse model, the peritoneal cancer index (PCI) was decreased to the same level using PIPAC or IV oxaliplatin. Systemic passage was lower in the PIPAC group. CONCLUSIONS: PIPAC with low-dose oxaliplatin is efficient in both in vitro and in vivo models of colon PM. Lower concentrations of chemotherapy are needed in PIPAC to achieve the same effect as IV chemotherapy on PCI. With a very low systemic oxaliplatin passage, this technique of drug delivery seems to be as effective as IV delivery for PM control.
Authors: Philippe Esquis; David Consolo; Guy Magnin; Philippe Pointaire; Philippe Moretto; Maria Dolores Ynsa; Jean-Luc Beltramo; Carole Drogoul; Michel Simonet; Laurent Benoit; Patrick Rat; Bruno Chauffert Journal: Ann Surg Date: 2006-07 Impact factor: 12.969
Authors: Daniel Göhler; Veria Khosrawipour; Tanja Khosrawipour; David Diaz-Carballo; Thomas Albert Falkenstein; Jürgen Zieren; Michael Stintz; Urs Giger-Pabst Journal: Surg Endosc Date: 2016-09-08 Impact factor: 4.584
Authors: Veria Khosrawipour; Tanja Khosrawipour; Alexander Jens Peter Kern; Aras Osma; Burak Kabakci; David Diaz-Carballo; Eckart Förster; Jürgen Zieren; Khashayar Fakhrian Journal: J Cancer Res Clin Oncol Date: 2016-09-02 Impact factor: 4.553
Authors: Wiebke Solass; Reinhold Kerb; Thomas Mürdter; Urs Giger-Pabst; Dirk Strumberg; Clemens Tempfer; Jürgen Zieren; Matthias Schwab; Marc André Reymond Journal: Ann Surg Oncol Date: 2013-09-05 Impact factor: 5.344
Authors: Mustafa Raoof; Gautam Malhotra; Adrian Kohut; Michael O'Leary; Paul Frankel; Thuy Tran; Marwan Fakih; Joseph Chao; Dean Lim; Yanghee Woo; Isaac B Paz; Michael Lew; Mihaela C Cristea; Lorna Rodriguez-Rodriguez; Yuman Fong; Andrew Blakely; Richard Whelan; Marc A Reymond; Amit Merchea; Thanh H Dellinger Journal: Ann Surg Oncol Date: 2021-08-13 Impact factor: 5.344
Authors: Florian Struller; Philipp Horvath; Wiebke Solass; Frank-Jürgen Weinreich; Dirk Strumberg; Marios K Kokkalis; Imma Fischer; Christoph Meisner; Alfred Königsrainer; Marc A Reymond Journal: Ther Adv Med Oncol Date: 2019-05-13 Impact factor: 8.168
Authors: Koen P Rovers; Robin J Lurvink; Emma Ce Wassenaar; Thomas Jm Kootstra; Harm J Scholten; Rudaba Tajzai; Maarten J Deenen; Joost Nederend; Max J Lahaye; Clément Jr Huysentruyt; Iris van 't Erve; Remond Ja Fijneman; Alexander Constantinides; Onno Kranenburg; Maartje Los; Anna Mj Thijs; Geert-Jan M Creemers; Jacobus Wa Burger; Marinus J Wiezer; Djamila Boerma; Simon W Nienhuijs; Ignace Hjt de Hingh Journal: BMJ Open Date: 2019-07-27 Impact factor: 2.692
Authors: Maciej Nowacki; Katarzyna Nowacka; Iwona Głowacka; Barbara Zegarska; Wojciech Zegarski Journal: Postepy Dermatol Alergol Date: 2019-08-30 Impact factor: 1.837
Authors: Signe Bremholm Ellebæk; Martin Graversen; Sönke Detlefsen; Lars Lundell; Claus W Fristrup; Per Pfeiffer; Michael B Mortensen Journal: Pleura Peritoneum Date: 2020-05-15